GLPG 0974
Alternative Names: GLPG-0974Latest Information Update: 10 Jul 2023
At a glance
- Originator Galapagos NV; GlaxoSmithKline
- Developer Galapagos NV
- Class Anti-inflammatories; Small molecules
- Mechanism of Action G-protein coupled receptor 43 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 10 Feb 2016 No development reported - Phase-I for Inflammatory bowel disease (In volunteers) in Belgium (PO)
- 10 Feb 2016 No development reported - Phase-II for Ulcerative colitis in Belgium (PO)
- 10 Feb 2016 No development reported - Phase-II for Ulcerative colitis in Czech Republic (PO)